



RECEIPT
FILE COPY
PATENT
454311-2200.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Steven D. HANES et al.
Serial No. : 09/507,242
Filed : February 18, 2000
For : CaESSI: A CANDIDA ALBICANS GENE, METHODS FOR
MARKING AND USING AND TARGETING IT AND ITS
EXPRESSION PRODUCTS FOR ANTIFUNGAL APPLICATIONS

745 Fifth Avenue
New York, New York 10151
Tel. (212) 588-0800

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231, on June 14, 2000

William S. Frommer, Reg. No. 25,506

Name of Applicant, Assignee or
Registered Representative


Signature

June 14, 2000

Date of Signature

RECEIVED

AUG 02 2000


TECH CENTER 1600/2900

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is a Request to correct the Filing Receipt issued in the above-identified application, in order to correct the noted inadvertent error. A copy of the Filing Receipt with the requested corrections noted thereon in red ink is enclosed.




PATENT
454311-2200.1

Please charge any fees required for this correction or credit any overpayment to Deposit

Account No. 50-0320.

Respectfully submitted,


FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By 
William S. Frommer
Reg. No. 25,506
Tel. (212) 588-0800

FILING RECEIPT



OC000000005159678

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/507,242	02/18/2000	1646	1446	454311-2200.1	5	23	5

Thomas J. Kowalski, Esq.
Frommer, Lawrence, & Haug, LLP
745 Fifth Avenue
New York, NY 10151

DOCKETED

Date Mailed: 06/06/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Steven D. Hanes, Albany, NY ;
Gina Devasahayam, Madras, INDIA ;
Vishnu Chaturvedi, Slingerlands, NY ;

RECEIVED
 AUG 02 2000
 TECH CENTER 1600/2900

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/121,246 02/23/1999

Foreign Applications

If Required, Foreign Filing License Granted 04/26/2000

Title

CaESSI: A

Candida albicans gene, methods for making and using, and targeting it and its expression products for antifungal applications

Preliminary Class


514

Data entry by : RIVERS, ANNETTE

Team : OIPE

Date: 06/06/2000





LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231



Bib Data Sheet


**UNITED STATES DEPARTMENT OF
COMMERCE**

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231**FILE COPY**

SERIAL NUMBER 09/507,242	FILING DATE 02/18/2000 RULE -	CLASS 514	GROUP ART UNIT 1646	ATTORNEY DOCKET NO. 454311-2200.1
------------------------------------	---	---------------------	-------------------------------	---

APPLICANTS
 Steven D. Hanes, Albany, NY ;
 Gina Devasahayam, Madras, INDIA;
 Vishnu Chaturvedi, Slingerlands, NY ;

**** CONTINUING DATA *******
 THIS APPLN CLAIMS BENEFIT OF 60/121,246 02/23/1999

**** FOREIGN APPLICATIONS *******

IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 04/26/2000

Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY NY	SHEETS DRAWING 5	TOTAL CLAIMS 23	INDEPENDENT CLAIMS 5
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials		

ADDRESS
 Thomas J. Kowalski, Esq.
 Frommer, Lawrence, & Haug, LLP
 745 Fifth Avenue
 New York, NY 10151

TITLE
 Caessi a albicans gene, methods for making and using, and targeting it and its expression products for antifungal applications

FILING FEE RECEIVED 1542	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit